-5%
Ibruxen (Ibrutinib), a generic version of Imbruvica, is a prescribed medication for treating specific cancers like Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma, and Marginal Zone Lymphoma (MZL). It’s also used to address conditions such as Waldenstrom Macroglobulinemia and Chronic Graft-Versus-Host Disease (cGVHD). Ibruxen is manufactured by Everest Pharma Ltd. in Bangladesh.
Ibrutinib is a targeted cancer therapy used to treat various conditions, including:
- Mantle Cell Lymphoma (MCL) in patients who have received prior therapy.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with or without 17p deletion.
- Waldenstrom Macroglobulinemia (WM).
- Marginal Zone Lymphoma (MZL) requires systemic therapy after previous anti-CD20-based treatment.
